PT Medikaloka Hermina Tbk (ISX:HEAL) Total Receivables: Rp1,400,077 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:HEAL PT Medikaloka Hermina Tbk ISX:HEAL
67 GF Score
Price Rp820.00
GF Value Rp1,586.03
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is PT Medikaloka Hermina Tbk Total Receivables?

PT Medikaloka Hermina Tbk ISX:HEAL 67 Total Receivables is Rp1,400,077 Mil as of Mar. 2026. GuruFocus rates ISX:HEAL with a GF Score™ of 67/100 and a GF Value™ of Rp1,586.03 (Significantly Undervalued). The stock has 5 warning signs investors should review.

PT Medikaloka Hermina Tbk's Total Receivables for the quarter that ended in Mar. 2026 was Rp1,400,077 Mil.

PT Medikaloka Hermina Tbk Total Receivables Related Terms

PT Medikaloka Hermina Tbk Total Receivables Historical Data

* Premium members only.

The historical data trend for PT Medikaloka Hermina Tbk's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Medikaloka Hermina Tbk Total Receivables Chart

PT Medikaloka Hermina Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,071,639.00 898,385.00 963,017.00 1,251,241.00 1,415,334.00

PT Medikaloka Hermina Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,293,744.00 1,326,575.00 1,370,182.00 1,415,334.00 1,400,077.00
ISX:HEAL
67GF Score
PT Medikaloka Hermina Tbk ISX:HEAL
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Medikaloka Hermina Tbk Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of Rp1,400,077 Mil mean?
PT Medikaloka Hermina Tbk (ISX:HEAL) has a Total Receivables of Rp1,400,077 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on PT Medikaloka Hermina Tbk and its competitors.
Is PT Medikaloka Hermina Tbk's Total Receivables too high?
PT Medikaloka Hermina Tbk's current Total Receivables is Rp1,400,077 Mil. Overall, PT Medikaloka Hermina Tbk has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Medikaloka Hermina Tbk's Total Receivables compare to HCA and THC?
PT Medikaloka Hermina Tbk's Total Receivables of Rp1,400,077 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Healthcare Providers & Services company?
A good Total Receivables depends on the Healthcare Providers & Services industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on PT Medikaloka Hermina Tbk and its competitors. PT Medikaloka Hermina Tbk's current Total Receivables is Rp1,400,077 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Medikaloka Hermina Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk (ISX:HEAL) is currently considered Significantly Undervalued. The stock's GF Value™ is Rp1,586.03, compared to a current price of Rp820.00 — trading 48.3% below its estimated fair value. The current Total Receivables is Rp1,400,077 Mil. PT Medikaloka Hermina Tbk's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For PT Medikaloka Hermina Tbk (ISX:HEAL), the current Total Receivables is Rp1,400,077 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Medikaloka Hermina Tbk (ISX:HEAL) Overvalued in 2026?

Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk stock appears to be undervalued. The current stock price of Rp820.00 is trading 48.3% below its estimated GF Value™ of Rp1,586.03. GuruFocus considers PT Medikaloka Hermina Tbk to be Significantly Undervalued.

Key valuation signals for ISX:HEAL:

  • Total Receivables: Rp1,400,077 Mil
  • GF Value™: Rp1,586.03 vs. price of Rp820.00 (48.3% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ISX:HEAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Medikaloka Hermina Tbk Business Description

Address Jalan Selangit B-10 Kavling No. 4, Hermina Tower, Kemayoran, Jakarta, IDN, 10610
PT Medikaloka Hermina Tbk is a private hospital group. It provides a range of medical services, including maternal and child health services, complex operating procedures, laboratory services, radiology facilities, and fertility treatments as well as general health services, pharmacies, diagnostic and emergency services. The company's geographical segment includes Kalimantan dan Sulawesi, Jawa, and Sumatera. It derives maximum revenue from the Jawa segment.
67GF Score

Get the complete analysis for ISX:HEAL

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp820.00
Price
Rp1,586.03
GF Value